Inflammatory cytokines and mediators

Inflammatory cytokines and mediators represent a broad class of signaling molecules, primarily proteins and lipid-derived compounds, that coordinate the host's response to infection, injury, and environmental challenges (StatPearls, 2023). These molecules, including tumor necrosis factors (TNFs), interleukins (ILs), interferons (IFNs), and chemokines, are secreted by various cells—most notably macrophages, T-cells, and endothelial cells—to initiate and amplify the inflammatory cascade (NIH, 2022). They function by binding to specific high-affinity receptors on target cells, triggering intracellular signaling pathways like NF-κB and JAK-STAT to alter gene expression (PubMed, 2021). In many chronic conditions, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, the persistent overproduction of these mediators leads to chronic inflammation and tissue destruction (Nature Reviews Immunology, 2018). Therapeutic strategies often involve monoclonal antibodies that neutralize specific cytokines or small molecules that inhibit their synthesis or downstream signaling, making them some of the most significant targets in modern pharmacology (NCBI, 2023).

Other names

Pro-inflammatory cytokinesInflammatory signaling moleculesInflammatory factorsInflammatory mediators

Drugs targeting these mediators typically act through ligand neutralization (monoclonal antibodies), receptor antagonism, or inhibition of biosynthetic enzymes (e.g., COX-2 inhibitors) and intracellular signaling pathways (e.g., JAK inhibitors) (StatPearls, 2023; PubMed, 2021).